Clinical Trial Update: A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of vincristine, escalating doses of irinotecan, temozolomide, and bevacizumab in pediatric and adolescent patients with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors in Children

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (CPT-11) (Irinotecan)
• Temozolomide (Temozolomide)
• Vincristine (vincristine)

Snippet

Sponsor: Children's Hospital Los Angeles | Conditions: Refractory Solid Tumors in Children | Phase 1 | Status: COMPLETED | Results posted: 2014-07-23